SAT-035 Small Molecule Allosteric Agonist of Relaxin Receptor Ml290 Demonstrates Antifibrotic Properties in Liver Fibrosis

Fibrosis is an underlying cause of cirrhosis and hepatic failure resulting in end stage liver disease with limited pharmacological therapeutic options. The beneficial effects of relaxin peptide treatment have been demonstrated previously in clinically relevant animal models of liver disease. However...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Endocr Soc
Autors principals: Kaftanovskaya, Elena, Ng, Hooi Hooi, Rivas, Bryan, Myhr, Courtney, Shupe, Thomas, Hu, Xin, Ferrer, Marc, Southall, Noel, Wilson, Kenneth, Marugan, Juan, Bishop, Colin, Agoulnik, Irina, Agoulnik, Alexander
Format: Artigo
Idioma:Inglês
Publicat: Endocrine Society 2019
Matèries:
Non-Steroid Hormone Signaling
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6552156/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-SAT-035
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars